Prevention of thrombosis in hypercoagulable patients undergoing microsurgery: A novel anticoagulation protocol.
Research article published in Journal of plastic, reconstructive & aesthetic surgery : JPRAS (2016)
Abstract
BACKGROUND: Hypercoagulable conditions are often considered relative contraindications to free flap reconstruction. This paper presents and critically examines a novel anticoagulation regimen developed to address this disease state. METHODS: Hypercoagulable patients who underwent free tissue transfer between 2007 and 2015 were identified. From 2011, all such patients were subjected to a novel anticoagulation protocol involving an intravenous bolus of 2000 U of unfractionated heparin prior to microvascular pedicle anastomosis, followed by a heparin infusion at 500 U/h, which was postoperatively increased to therapeutic levels. Patients were discharged on full anticoagulation for 1 month. Patients prior to 2011 received only subcutaneous heparin. Outcomes in patients receiving this novel anticoagulation protocol were compared to those of patients receiving standard therapy (postoperative subcutaneous heparin). RESULTS: Twenty-three hypercoagulable patients underwent reconstruction with 32 flaps. Eleven patients were administered the novel protocol. No thromboses were noted in the novel protocol cohort, while three thrombotic events occurred in the control cohort (0% vs. 17.6%, p = 0.23). No flaps were salvaged after thrombosis. All losses occurred in the control cohort (0% vs. 17.6%, p = 0.23). The novel protocol cohort was more likely to have postoperative red blood cell transfusions (72.6% vs. 16.7%, p = 0.007), hematomas (26.7% vs. 0%, p = 0.04), and lower mean hemoglobin nadirs [6.9 (1.0) vs. 8.9 ± 1.8 g/dL, p = 0.01]. CONCLUSION: The key approach to hypercoagulable patients is likely prevention over treatment. Patients who received prophylactic heparin infusions had clinically lower rates of thrombotic events and flap loss. However, this encouraging finding must be balanced with the increased risk for postoperative bleeding complications.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Zusammenfassung
Hypercoagulable conditions are often considered relative contraindications to free flap reconstruction. This paper presents and critically examines a novel anticoagulation regimen developed to address this disease state.
Warum dies für die Hirudotherapie relevant ist
Dieser Artikel untersucht ein neuartiges systemisches Antikoagulationsprotokoll unter Verwendung von intravenösem unfraktioniertem Heparin zur Thromboseprophylaxe bei hyperkoagulablen Patienten, die sich einer freien Gewebeverpflanzung (Mikrochirurgie) unterziehen. Während das neuartige Protokoll im Vergleich zu subkutan verabreichtem Standardheparin niedrigere thrombotische Ereignisraten zeigte, war es mit signifikant höheren Risiken für Blutungskomplikationen verbunden, einschließlich Hämatomen und Transfusionen. Für die Hirudotherapie ist diese Studie klinisch relevant, da die mikrovaskuläre freie Lappenrekonstruktion ein Haupteinsatzgebiet ist, in dem medizinische Blutegel zur Rettung venös gestauten Gewebes eingesetzt werden. Das Verständnis der systemischen Risiken chirurgischer Antikoagulation bietet einen scharfen Kontrast zu den lokalisierten antikoagulatorischen Effekten der Blutegeltherapie. Allerdings weist diese Studie keine direkte Verbindung zu Blutegeln auf und bewertet ausschließlich systemische Heparinprotokolle, ohne das Blutegelsekretom oder die Hirudotherapie zu erwähnen.
Zitation
Prevention of thrombosis in hypercoagulable patients undergoing microsurgery: A novel anticoagulation protocol.
Nelson et al. · Journal of plastic, reconstructive & aesthetic surgery : JPRAS, 2016
Verwandter klinischer Kontext
Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist
Zur ASH-Bibliothek hinzugefügt: May 28, 2026 · Letzte Aktualisierung der Website: June 18, 2026